# Hyperimmune Plasma in Patients With COVID-19 Severe Infection

> **NCT04385043** · PHASE2,PHASE3 · UNKNOWN · sponsor: **University of Catanzaro** · enrollment: 400 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **OTHER:** plasma hyperimmune
- **DRUG:** standard therapy

## Key facts

- **NCT ID:** NCT04385043
- **Lead sponsor:** University of Catanzaro
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-01
- **Primary completion:** 2020-10-15
- **Final completion:** 2021-05-15
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2020-05-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04385043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04385043, "Hyperimmune Plasma in Patients With COVID-19 Severe Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04385043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*